ROSEN, A LEADING LAW FIRM, Encourages Investors in Humacyte, Inc. to secure a lawyer before the important Jan. 17 deadline for the securities class action

New York, New York–(Newsfile Corp. – January 1, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA ) between May 10, 2024 and October 17, 2024, both dates inclusive (“Class Period”), on an important January 17, 2025, the deadline of the chief prosecutor.

SO WHAT: If you purchased Humacyte securities during the Class Period, you may be entitled to compensation without paying any fees or out-of-pocket expenses through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Humacyta class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than January 17, 2025. The lead plaintiff is the representative party that acts on behalf of the other class members in the conduct of the litigation.

WHY ROSEN’S LAW: We encourage investors to choose a qualified advisor with experience in successful leadership roles. Often the firms issuing the notices do not have comparable experience, resources or any significant recognition from their peers. Many of these firms do not actually initiate securities class action lawsuits, but are merely brokers who refer clients or are partners with the law firms that actually initiate the cases. Be wise in choosing an advisor. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and equity derivative litigation. The Rosen Law Firm secured the largest securities class action settlement to date against a Chinese company at the time. The Rosen Law Firm is ranked #1 by ISS Securities Class Action (WA:) Services for numerous securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured more than $438 million for investors. In 2020, founding partner Laurence Rosen was named a Law360 Claimant Bar Association Titan. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the complaint, during the Lecture Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Humacyte’s facility in Durham, North Carolina did not follow good manufacturing practices, including quality assurance and microbial testing; (2) the Food and Drug Administration’s (“FDA”) review of the Biologics License Application (“BLA”) would be delayed while Humacyte addressed these deficiencies; and (3) as a result, there was a substantial risk to FDA approval of the acellular Tissue Engineered Vessel (“ATEV”) for vascular trauma; and (4) as a result of the foregoing, the defendants’ positive statements about Humacyte’s business, operations and prospects were materially misleading and/or lacked a reasonable basis. When the true details came to market, the lawsuit alleges, investors suffered damages.

To join the Humacyta class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action.

No class is certified. Until the class is certified, you will not be represented by an attorney unless you retain one. You can choose a lawyer of your choice. You can also remain an absent member of the class and do nothing at this time. An investor’s ability to participate in a potential future recovery does not depend on whether it is the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ /www.facebook.com/rosenlawfirm/.

Advertising of lawyers. Previous results do not guarantee a similar outcome.

——————————–

To view the original version of this press release, visit https://www.newsfilecorp.com/release/235757